Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparative transcriptomic analysis identifies distinct molecular signatures and regulatory networks of chondroclasts and osteoclasts.

Arthritis research & therapy·2020

Same author

Deletion of Wnt5a in osteoclasts results in bone loss through decreased bone formation.

Annals of the New York Academy of Sciences·2020

Same author

Articular cartilage protection in Ctsk<sup>-/-</sup> mice is associated with cellular and molecular changes in subchondral bone and cartilage matrix.

Journal of cellular physiology·2018

Same author

Role of Cbl-PI3K Interaction during Skeletal Remodeling in a Murine Model of Bone Repair.

PloS one·2015

Same author

Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling.

Journal of cellular physiology·2015

Same author

Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Paget's disease of bone.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2008

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Biomarkers in Osteosarcoma.

Colin Kong¹, Marc F Hansen

¹Center For Molecular Medicine, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030.

Expert Opinion on Medical Diagnostics

|September 28, 2011

Summary

This summary is machine-generated.

Osteosarcoma survival rates have plateaued despite advances. New molecular markers are needed to identify patients resistant to current treatments for better prognosis and targeted therapies.

More Related Videos

Methods to Enable Spatial Transcriptomics of Bone Tissues

Methods to Enable Spatial Transcriptomics of Bone Tissues

Published on: May 3, 2024

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Related Experiment Videos

Last Updated: Jun 12, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Methods to Enable Spatial Transcriptomics of Bone Tissues

Methods to Enable Spatial Transcriptomics of Bone Tissues

Published on: May 3, 2024

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Area of Science:

Oncology
Bone Cancer Research
Molecular Pathology

Background:

Osteosarcoma is the most common primary bone tumor and a significant cause of cancer death in children and young adults.
Current multidisciplinary treatments have improved survival, but progress has stalled in recent decades.
Existing prognostic markers, including metastasis detection and chemotherapy response, are insufficient for a subset of patients.

Purpose of the Study:

To highlight the critical need for novel prognostic markers in osteosarcoma.
To emphasize the potential of molecular analysis for identifying treatment-resistant patient groups.
To underscore the necessity for advanced classification systems and therapeutic targets.

Main Methods:

Review of current osteosarcoma treatment outcomes and prognostic factors.
Analysis of the limitations of existing clinical and histopathological markers.
Discussion of the potential of molecular profiling and comprehensive analysis technologies.

Main Results:

Despite initial improvements, osteosarcoma survival rates have not significantly advanced in over 20 years.
Approximately 20% of patients without distant metastases at diagnosis remain resistant to current therapies.
Current molecular marker research has not yet surpassed the prognostic value of established clinical markers.

Conclusions:

There is an urgent need for improved prognostic markers to guide treatment for osteosarcoma patients.
Molecular analysis holds promise for identifying patients who may benefit from alternative therapeutic strategies.
Developing comprehensive classification systems and novel therapeutic targets is crucial for advancing osteosarcoma care.